Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trabectedin (T) in Combination With Pegylated Liposomal Doxyrubicin (PLD) Compared to Cisplatin Hypersensitivity (CH) Treatment in Recurrent Ovarian Cancer Patients Allergic to Carboplatin

NCT05512676 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT05512676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05512676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trabectedin (T) in Combination With Pegylated Liposomal Doxyrubicin (PLD) Compared to Cisplatin Hypersensitivity (CH) Treatment in Recurrent Ovarian Cancer Patients Allergic to Carboplatin
Lead sponsor
Oslo University Hospital
Phase
Observational
Overall status
Completed
Start date
March 7, 2016
Completion date
August 1, 2022
Enrollment
40 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapeutic toxicity, chemotherapy effect, chemotherapy-induced nausea and vomiting, chemotherapy-induced neutropenia, ovarian neoplasm